Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis

Table 1 General aspects of all non-alcoholic steatohepatitis cases n (%)

Nonalcoholic steatohepatitis (n = 70)
Average age (yr)	47.9 ± 8.74
Gender (male/female)	36/34
Hepatomegaly	16 (23.9)
BMI (kg/m2)	30.4 ± 4.79
Normal weight (BMI < 24.9 kg/m2)	3 (4.30)
Overweight (BMI = 25-29.9 kg/m2)	34 (48.5)
Obese (BMI = 30-39.9 kg/m2)	29 (41.4)
Morbid obese (BMI > 40 kg/m2)	4 (5.80)
Waist/hip cir (E > 0.90, K > 0.85)	49 (71)
Systolic blood pressure (mmHg)	124 ± 16.2
Diastolic blood pressure (mmHg)	75.6 ± 11.9
Hypertension	21 (30.4)
HDL-cholesterol (mg/dL)	46.3 ± 8.07
Low-HDL-cholesterol	28 (40.5)
Triglycerides (mg/dL)	163 ± 79.5
Hypertriglyceridemia	36 (52.1)
Fasting glucose (mg/dL)	107 ± 26.2
Diabetes mellitus	20 (28.8)
Fasting insulin (μU/mL)	16.6 ± 13.0
Homeostatic model assessment-insulin resistance value	3.91 ± 2.45
Fasting c-peptid	4.35 ± 2.15
aspartate aminotransferase (U/L)	48.2 ± 23.9
Alanine aminotransferase (U/L)	76.2 ± 35.2
Gama glutamyl transpeptidase (U/L)	59.2 ± 46.8
Alkaline phosphatase (U/L)	93.4 ± 32.3
İnsulin resistance	30 (43.4)
Metabolic syndrome	46 (66.6)

This table shows that numbers of non obese patients are much higher than obese patients and 33.4% of non-alcoholic steatohepatitis patients have no metabolic syndrome. BMI: Body mass index; HDL: High-density lipoprotein.